The correlation of lncRNA SNHG16 with inflammatory cytokines, adhesion molecules, disease severity, and prognosis in acute ischemic stroke patients

Chen Xie | Bin Zhu | Juxian Gu | Muhua Sun

1Department of Traditional Chinese Medicine, School of Medicine, Xingtai Medical College, The First Affiliated Hospital of Xingtai Medical College, Xingtai, China
2Department of Neurology, School of Medicine, Xingtai Medical College, The First Affiliated Hospital of Xingtai Medical College, Xingtai, China
3Department of Neurology, Cangzhou Central Hospital, Cangzhou, China
4Department of Peripheral Vascular, Mudanjiang Hospital of Traditional Chinese Medicine, Mudanjiang, China

Correspondence
Chen Xie, Department of Traditional Chinese Medicine, The First Affiliated Hospital of Xingtai Medical College, No. 376 Shunde Road, Xiangdu District, Xingtai 054001, China.
Email: lexie04934118178@163.com

Abstract

Background: Long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG16) is involved in the pathogenesis of acute ischemic stroke (AIS) through the regulation of brain endothelial cell viability, inflammation, atherosclerotic plaque formation, and neural apoptosis. This study aimed to evaluate the prognostic value of lncRNA SNHG16 in AIS patients.

Methods: Newly diagnosed AIS patients (N = 120) were serially recruited. Their lncRNA SNHG16 expressions in peripheral blood mononuclear cells (PBMCs) were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR); serum inflammatory cytokines and adhesion molecules were determined using enzyme-linked immunosorbent assay (ELISA). The accumulating recurrence-free survival (RFS) and overall survival (OS) were analyzed. Moreover, controls (N = 60) were recruited and their lncRNA SNHG16 expressions in PBMCs were detected.

Results: LncRNA SNHG16 was declined in AIS patients compared to controls (p < 0.001). Moreover, lncRNA SNHG16 was not related to any comorbidities in AIS patients (all p > 0.05). Interestingly, lncRNA SNHG16 was negatively related to tumor necrosis factor alpha (TNF-α) (p < 0.001), interleukin 6 (IL-6) (p = 0.013), and intracellular cell adhesion molecule-1 (ICAM-1) (p = 0.024), while positively correlated with interleukin 10 (IL-10) (p = 0.022) in AIS patients. Besides, lncRNA SNHG16 was inversely associated with the National Institutes of Health Stroke Scale (NIHSS) score in AIS patients (p = 0.003). During the follow-up period, in 14 (11.7%) patients occurred recurrence and 5 (4.2%) patients died. Unexpectedly, lncRNA SNHG16 was not associated with accumulating RFS (p = 0.103) or OS (p = 0.150) in AIS patients.

Conclusion: LncRNA SNHG16 relates to lower inflammatory cytokines, adhesion molecules, and milder disease severity, but fails to predict prognosis in AIS patients.

KEYWORDS
acute ischemic stroke, disease severity, inflammatory cytokines, long non-coding RNA small nucleolar RNA host gene 16, prognosis
1 | INTRODUCTION

Acute ischemic stroke (AIS), as one of the critical cerebrovascular diseases, accounts for 7.63 million newly diagnosed cases and 3.29 million mortality cases in 2019 globally. Despite the recent advances in AIS management (such as intravenous thrombolysis, mechanical thrombectomy, anticoagulation therapy, etc.), the narrowing therapeutic window for AIS patients remains a huge challenge in the clinical practice. Even for those AIS patients with successful reperfusion, the recurrence and mortality rates remain high. Hence, it is necessary to identify novel biomarkers to monitor disease progression and improve AIS management.

Long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG16) is first reported in carcinomas. Meanwhile, several recent studies report that IncRNA SNHG16 also participates in AIS pathogenesis via the regulation of brain endothelial cell proliferation, inflammatory cytokine production, and atherosclerotic plaque formation. For instance, IncRNA SNHG16 promotes human brain endothelial cell proliferation, while suppressing cell apoptosis through regulation of the microRNA-15a-5p/bcl-2 axis. Besides, IncRNA SNHG16 regulates the expression of inflammatory cytokines (including tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6)) in vitro. Furthermore, IncRNA SNHG16 regulates the nuclear factor-kappa B (NF-κB) pathway in macrophages and further mediates progression of atherosclerosis. In the clinical field, only two recent studies have reported that IncRNA SNHG16 is dysregulated in atherosclerotic patients. However, the clinical role of IncRNA SNHG16 in AIS patients remains unclear and requires exploration.

Hence, this study was intended to explore the association of IncRNA SNHG16 with inflammatory cytokines, adhesion molecules, disease severity, recurrence, and death in AIS patients.

2 | METHODS

2.1 | Participants

This study serially recruited 120 newly diagnosed AIS patients treated in the hospital within 24 h after symptoms onset from July 2016 to December 2020. The recruitment criteria were set as: (a) newly diagnosed as AIS according to the American Stroke Association Guideline; (b) aged over 18 years; (c) had no intracranial hemorrhage which was confirmed by the images of computed tomography (CT) scan or magnetic resonance angiography (MRA); (d) willing to provide peripheral blood (PB) samples; and (e) able to understand the study and willing to be followed up regularly. The patients who presented with severe infection, or had a prior history of malignant disease, were excluded from the study. Additionally, the study also enrolled 60 subjects who had at least two high-risk factors of stroke (including history of smoke, hypertension, hyperlipidemia, hyperuricemia, diabetes mellitus (DM), and chronic kidney disease (CKD)) as controls. To eliminate the potential bias, age and gender of the controls were matched to those of the AIS patients: the age limitation was 50–80 years; the gender ratio was 4:1 (male vs. female). The controls who had a history of stroke, or had met the exclusion criteria for AIS patients, were also ineligible for the study. The written informed consents were collected from all participants or the guardians. The study was permitted by the Ethics Committee of The First Affiliated Hospital of Xingtai Medical College.

2.2 | Data documentation

Clinical characteristics of AIS patients were obtained for study analysis, including age, gender, body mass index (BMI), history of smoke, comorbidities, and National Institutes of Health Stroke Scale (NIHSS) score. NIHSS score was collected within 24 h after hospitalization to evaluate the disease severity.

2.3 | Peripheral blood (PB) collection and detection

Peripheral blood (PB) was sampled from AIS patients immediately after hospitalization and from controls after recruitment, respectively. After PB collection, peripheral blood mononuclear cells (PBMCs) were separated from PB of all participants, then RNA was extracted using QIAamp RNA Blood Mini Kit (Qiagen, Germany) to evaluate IncRNA SNHG16 expression. The IncRNA SNHG16 expression was assessed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). In brief, the reverse transcription was performed using iScript™ cDNA Synthesis Kit (Bio-Rad) and the qPCR was conducted using KOD SYBR® qPCR Mix (Toyobo). The relative expression of IncRNA SNHG16 was calculated by the 2−ΔΔCt method where glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as an internal reference. The detailed sequences of primers were in line with those of a previous study and displayed as follows: IncRNA SNHG16, forward, 5′-TGGTTCATGCGGGAAGTCAAC-3′; reverse, 5′-ATGGGACATGAGCTGTCATC-3′; GAPDH, forward, 5′-AAGTTAGAAGGCGAGCTTCA-3′; reverse, 5′-AATGAAAGGCTTTTGATACG-3′. Besides, serum was isolated from PB of AIS patients to detect the levels of inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-10), and adhesion molecules (intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)) by enzyme-linked immunosorbent assay (ELISA) using commercial Human ELISA Kits (Bio-Techne China Co., Ltd.). The experimental process was in stringent accordance with the instructions from the manufacturer.

2.4 | Follow-up

Clinical follow-up for AIS patients was carried out by clinic visit or telephone according to the AIS Guideline. The continuous
follow-up was performed until April 30, 2021. The median follow-up
duration was 18 months, with the range of 3–52 months. Based on
the follow-up information, recurrence-free survival (RFS) and overall
survival (OS) were imputed. Patients who did not experience a RFS
or OS event at the time of final analysis were censored at the last
date of disease assessment.

2.5 | Statistics

Statistical analysis was completed by SPSS V.24.0 (IBM Corp.), and
graphs were constructed by GraphPad Prism V.6.01 (GraphPad
Software Inc.) and R V.4.0.5 (ggplot2 package, available at www.r-
project.org). Mann–Whitney U test was used for the comparison
of IncRNA SNHG16 expression between two groups. Spearman’s rank
correlation test or Mann–Whitney U test was applied for correla-
tion between two variables. Kaplan-Meier curve was plotted for the
display of RFS and OS, and log-rank test was used for the determina-
tion of RFS and OS differences between groups. Cox’s proportional
hazard regression was carried out for prognostic factor analysis. A
value of \( p < 0.05 \) was considered as statistically significant.

3 | RESULTS

3.1 | Clinical features

Among recruited AIS patients, the mean age was 64.4 ± 9.4 years
(Table 1). Meanwhile, there were 35 (29.2%) females and 85 (70.8%)
males. Moreover, in 97 (80.8%), 59 (49.2%), 60 (50.0%), 26 (21.7%),
and 27 (22.5%) patients occurred the comorbidities of hyper-
tension, hyperlipidemia, hyperuricemia, DM, and CKD, respectively.
Furthermore, the median NIHSS score was 6.0 with the interquartile
range (IQR) of 4.0–11.0. The detailed clinical features of AIS patients
are exhibited in Table 1.

3.2 | IncRNA SNHG16 expression and its
relationship with comorbidity

IncRNA SNHG16 was decreased in AIS patients compared to controls
[median (IQR): 0.503 (0.327–0.770) vs. 1.003 (0.844–1.564),
\( p < 0.001 \) (Figure 1)]. Then, further correlation analyses displayed
that IncRNA SNHG16 was not related to any comorbidities in AIS
patients (all \( p > 0.05 \) (Table 2).

3.3 | Correlation of IncRNA SNHG16 with
inflammatory cytokines, adhesion molecules, and
disease severity

IncRNA SNHG16 was negatively related to TNF-\( \alpha \) \( (r_s = -0.327,
\ p < 0.001) \), IL-6 \( (r_s = -0.227, \ p = 0.013) \), ICAM-1 \( (r_s = -0.206,
\ p = 0.024) \), while positively correlated with IL-10 \( (r_s = 0.209,
\ p = 0.022) \); there was no correlation of IncRNA SNHG16 with
IL-1\( \beta \) \( (r_s = -0.158, \ p = 0.086) \) or VCAM-1 \( (r_s = -0.164, \ p = 0.074) \)
(Figure 2A–F).

Moreover, IncRNA SNHG16 was inversely associated with NIHSS
score \( (r_s = -0.269, \ p = 0.003) \) (Figure 3). Also, IncRNA SNHG16 was
negatively related to stroke severity based on NIHSS scores in AIS
patients \( (r_s = -0.219, \ p = 0.016) \) (Figure S1).

3.4 | Association of IncRNA SNHG16 with
recurrence and death

The median follow-up was 18 months ranging from 3 to 52 months.
At the last follow-up date, in 14 (11.7%) patients occurred recur-
rence, and 5 (4.2%) patients died. K-M curves and log-rank test
analyses displayed that there was no association of IncRNA SNHG16
with accumulating RFS \( (p = 0.103) \) (Figure 4) or accumulating OS
\( (p = 0.150) \) (Figure 5).

---

**TABLE 1** Characteristics of AIS patients

| Items                        | AIS patients (N = 120) |
|-----------------------------|------------------------|
| **Demographics**            |                        |
| Age (years), mean ± SD      | 64.4 ± 9.4             |
| Gender, n (%)               |                        |
| Female                      | 35 (29.2)              |
| Male                        | 85 (70.8)              |
| BMI (kg/m\(^2\)), mean ± SD | 23.9 ± 2.9             |
| History of smoke, n (%)     | 59 (49.2)              |
| **Comorbidities**           |                        |
| Hypertension, n (%)         | 97 (80.8)              |
| Hyperlipidemia, n (%)       | 59 (49.2)              |
| Hyperuricemia, n (%)        | 60 (50.0)              |
| DM, n (%)                   | 26 (21.7)              |
| CKD, n (%)                  | 27 (22.5)              |
| **Disease features**        |                        |
| NIHSS score, median (IQR)   | 6.0 (4.0–11.0)         |
| **Cytokines**               |                        |
| TNF-\( \alpha \) (pg/ml), median (IQR) | 100.4 (75.3–143.6)  |
| IL-1\( \beta \) (pg/ml), median (IQR)  | 2.0 (1.3–2.8)         |
| IL-6 (pg/ml), median (IQR)  | 15.2 (10.9–22.0)       |
| IL-10 (pg/ml), median (IQR) | 60.2 (42.1–92.7)       |
| ICAM-1 (ng/ml), median (IQR)| 84.9 (56.6–125.6)      |
| VCAM-1 (ng/ml), median (IQR)| 554.4 (447.4–752.8)    |

Abbreviations: AIS, acute ischemic stroke; BMI, body mass index; CKD, chronic kidney disease; DM, diabetes mellitus; ICAM-1, intercellular
adhesion molecule-1; IL-10, interleukin 10; IL-1\( \beta \), interleukin-1 beta; IL-6, interleukin 6; IQR, interquartile range; NIHSS, National Institutes
of Health Stroke Scale; SD, standard deviation; TNF-\( \alpha \), tumor necrosis
factor alpha; VCAM-1, vascular cell adhesion molecule-1.
LncRNA SNHG16 has been observed to be dysregulated in atherosclerotic diseases. For example, LncRNA SNHG16 is overexpressed in oxidized low-density lipoprotein (ox-LDL) treated THP-1 macrophages and vascular smooth muscle cells (VSMCs), while its downregulation is reported in endothelial cells and neural cells following oxygen-glucose deprivation.\textsuperscript{10,12,16,17} Clinically, aberrant expression of LncRNA SNHG16 has been reported in atherosclerosis patients.\textsuperscript{12,13} While no relevant study has detected the expression of LncRNA SNHG16 in AIS patients. In the current study, it was discovered that LncRNA SNHG16 was downregulated in AIS patients compared to controls. The possible reason to explain this finding was that LncRNA SNHG16 promoted microvascular endothelial cell proliferation, suppressed the migration of VSMCs, and inhibited the production of inflammatory cytokines, which further slowed the progression of atherosclerosis in AIS patients.\textsuperscript{10–13} Thus, LncRNA SNHG16 was negatively associated with AIS risk.

Moreover, it was also observed that LncRNA SNHG16 was negatively linked with TNF-\textgreekalpha, IL-6, ICAM-1, and NIHSS score, while positively related to IL-10 in AIS patients, which could be explained as that: (a) LncRNA SNHG16 regulated multiple microRNAs (such as microRNA-146a-5p, microRNA-370-3p, microRNA-105-5p, etc.) and signaling pathways (such as NF-\textkappaB and janus kinase 1/signal transducer and activator of transcription 3 (JAK1/STAT-3) pathways) to suppress inflammatory cytokines and adhesion molecules in AIS patients.\textsuperscript{11,18,19} (b) Less vascular inflammation was related to a lower risk of rupture of the atherosclerotic plaque in the cranial blood vessels and further led to a preserved neurological function and milder disease severity (reflected by the NIHSS score) in AIS patients.\textsuperscript{20–22} (c) LncRNA SNHG16 was negatively related to adhesion molecules as discussed earlier, which might further inhibit the migration and proliferation of VSMCs, thereby suppressing the formation of foam cell in subendothelial space and preventing the progression of atherosclerosis, thus leading to lower disease severity in AIS patients.\textsuperscript{23}

In order to determine the prognostic value of LncRNA SNHG16 in AIS management, the recurrence and mortality events were recorded during the follow-up period, then RFS and OS were analyzed by K-M curve and log-rank tests. Subsequently, it was observed that LncRNA SNHG16 high was not correlated with accumulating RFS or OS in AIS patients, although a tendency between LncRNA SNHG16 and the favorable prognosis was discovered. The possible reasons of these findings were: (a) LncRNA SNHG16 might prevent the occurrence and development of atherosclerotic plaques in the cranial vasculature, therefore reducing the risk of vascular occlusion, oxidative stress, and neural apoptosis, which was further related to a longer RFS and OS in AIS patients to some degree.\textsuperscript{24–27} (b) The relatively small sample size of the current study might contribute to the low statistical power, also multiple factors might affect the AIS prognosis, thus only a tendency (but without statistical significance) of LncRNA SNHG16 correlating with accumulating RFS and OS in AIS patients was observed.
The present study exhibits several clinical implications. The measurement of lncRNA SNHG16 could provide certain evidence for assessing disease severity and progression in AIS patients. Moreover, our study suggested that lncRNA SNHG16 might participate in AIS pathogenesis, while further molecular experiments were warranted. However, several limitations occurred in the current study. For instance, healthy subjects were not recruited in the current study to comprehensively analyze the expression of lncRNA SNHG16 among them. Moreover, the correlation of lncRNA SNHG16 with atherosclerotic plaques in AIS patients required further investigation. Furthermore, the modified Rankin scale (mRS) at 3 months after the first stroke in AIS patients was not recorded in the current study, which might be improved in the forthcoming studies.
In conclusion, lncRNA SNHG16 relates to lower inflammatory cytokines, adhesion molecules, and milder disease severity, but fails to predict prognosis in AIS patients.

ACKNOWLEDGEMENT
None.

CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest.

DATA AVAILABILITY STATEMENT
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID
Chen Xie https://orcid.org/0000-0001-6189-7956

REFERENCES
1. Collaborators GBDS. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet Neurol. 2021;20(10):795-820.

2. Mendelson SJ, Prabhakaran S. Diagnosis and management of transient ischemic attack and acute ischemic stroke: a review. JAMA. 2021;325(11):1088-1098.

3. Rabinstein AA. Update on treatment of acute ischemic stroke. Continuum (Minneap Minn). 2020;26(2):268-286.

4. Zhu F, Gauberti M, Marnat G, et al. Time from I.V. Thrombolysis to thrombectomy and outcome in acute ischemic stroke. Ann Neurol. 2021;89(3):511-519.

5. Singh RJ, Chen S, Ganesh A, Hill MD. Long-term neurologic, vascular, and mortality outcomes after stroke. Int J Stroke. 2018;13(8):787-796.

6. Khanevski AN, Bjerkreim AT, Novotny V, et al. Recurrent ischemic stroke: incidence, predictors, and impact on mortality. Acta Neurol Scand. 2019;140(1):3-8.

7. Gong CY, Tang R, Nan W, Zhou KS, Zhang HH. Role of SNHG16 in human cancer. Clin Chim Acta. 2020;503:175-180.

8. Chen ZY, Wang XY, Yang YM, et al. LncRNA SNHG16 promotes colorectal cancer cell proliferation, migration, and epithelial-mesenchymal transition through miR-124-3p/MCP-1. Gene Ther. 2020;1-13. Online ahead of print.

9. Du SM. The SNHG16/miR-30a axis promotes breast cancer cell proliferation and invasion by regulating RRM2. Neoplasma. 2020;67(3):567-575.

10. Teng H, Li M, Qian L, Yang H, Pang M. Long noncoding RNA SNHG16 inhibits the oxygenglucone deprivation and reoxgyenation induced apoptosis in human brain microvascular endothelial cells by regulating miR15a5p/bcl2. Mol Med Rep. 2020;22(4):2685-2694.

11. Zhou Z, Zhu Y, Gao G, Zhang Y. Long noncoding RNA SNHG16 targets miR-146a-5p/CCL5 to regulate LPS-induced WI-38 cell apoptosis and inflammation in acute pneumonia. Life Sci. 2019;228:189-197.

12. An JH, Chen ZY, Ma QL, Wang HJ, Zhang JQ, Shi FW. LncRNA SNHG16 promoted proliferation and inflammatory response of macrophages through miR-17-5p/NF-kappa B signaling pathway in patients with atherosclerosis. Eur Rev Med Pharmacol Sci. 2019;23(19):8665-8677.

13. Lin Y, Tian G, Zhang H, et al. Long non-coding RNA SNHG16 regulates human aortic smooth muscle cell proliferation and migration via sponging miR-205 and modulating Smad2. J Cell Mol Med. 2019;23(10):6919-6929.

14. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947.

15. Wen Q, Zhao L, Wang T, et al. LncRNA SNHG16 drives proliferation and invasion of papillary thyroid cancer through modulation of miR-497. Onco Targets Ther. 2019;12:699-708.

16. Wang Y, Yang Y, Zhang T, et al. LncRNA SNHG16 accelerates atherosclerosis and promotes ox-LDL-induced VSMC growth via the miRNA-22-3p/HMG82 axis. Eur J Pharmacol. 2022;915:174601.

17. Cao X, Ma J, Li S. Mechanism of IncRNA SNHG16 in oxidative stress and inflammation in oxygen-glucose deprivation and reoxygenation-induced SK-N-SH cells. Bioengineered. 2022;13(3):5021-5034.

18. Zhang J, Mao F, Zhao G, Wang H, Yan X, Zhang Q. Long non-coding RNA SNHG16 promotes lipopolysaccharides-induced acute pneumonia in A549 cells via targeting miR-370-3p/IGF2 axis. Int Immunopharmacol. 2020;78:106065.

19. Li H, Quan F, Zhang P, Shao Y. Long non-coding RNA SNHG16, binding with miR-106b-5p, promoted cell apoptosis and inflammation in allergic rhinitis by up-regulating leukemia inhibitory factor to activate the JAK1/STAT3 signaling pathway. Hum Exp Toxicol. 2021;40(12_suppl):S233-S245.

20. Sterpetti AV. Inflammatory cytokines and atherosclerotic plaque progression. Therapeutic implications. Curr Atheroscler Rep. 2020;22(12):75.

21. Mury P, Chirico EN, Mura M, Millon A, Canet-Souls E, Pialoux V. Oxidative stress and inflammation, key targets of atherosclerotic plaque progression and vulnerability: potential impact of physical activity. Sports Med. 2018;48(12):2725-2741.

22. Spacek M, Zemanek D, Hutyra M, Sluka M, Taborsky M. Vulnerable atherosclerotic plaque - A review of current concepts and advanced imaging. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;162(1):10-17.

23. Malekomohammad K, Sewell RDE, Rafieian-Kopaei M. Antioxidants and atherosclerosis: mechanistic aspects. Biomolecules. 2019;9(8):301.

24. Uzdensky AB. Apoptosis regulation in the penumbra after ischemic stroke: expression of pro- and ant apoptotic proteins. Apoptosis. 2019;24(9-10):687-702.
25. Datta A, Sarmah D, Mounica L, et al. Cell death pathways in ischemic stroke and targeted pharmacotherapy. *Transl Stroke Res*. 2020;11(6):1185-1202.

26. Orellana-Urzúa S, Rojas I, Libano L, Rodrigo R. Pathophysiology of ischemic stroke: role of oxidative stress. *Curr Pharm Des*. 2020;26(34):4246-4260.

27. Duan J, Gao S, Tu S, Lenahan C, Shao A, Sheng J. Pathophysiology and therapeutic potential of NADPH oxidases in ischemic stroke-induced oxidative stress. *Oxid Med Cell Longev*. 2021;2021:6631805.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.